A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs PF 6409577 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 26 May 2015 Planned number of patients changed from 64 to 72 as reported by ClinicalTrials.gov record.
    • 26 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top